Aug 10, 2018 by Brian Orelli, PhDHere's Why Endologix Plummeted 37% TodayEarnings guidance isn't what it used to be.
Aug 9, 2018 by Brian Orelli, PhDDiplomat Pharmacy's Stronger Top Line Doesn't Help Its Bottom LineHigher expenses turn solid revenue growth into a second-quarter loss for the pharmacy benefit manager and specialty pharmacy combination.
Aug 9, 2018 by Brian Orelli, PhDHere's Why Verastem Jumped Higher TodayHint: It has nothing to do with yesterday's earnings release.
Aug 8, 2018 by Brian Orelli, PhDGenomic Health Starts Its MarathonThe CEO sees steady growth as the company increases volume of its cancer tests and improves reimbursement from payers.
Aug 8, 2018 by Brian Orelli, PhDBecton, Dickinson Sees Synergies From Bard With More to ComeNext up: revenue synergies.
Aug 7, 2018 by Brian Orelli, PhDEmergent BioSolutions Makes Up for Last QuarterTiming issues in the first quarter are a thing of the past.
Aug 7, 2018 by Brian Orelli, PhDBioMarin Pharmaceutical Sets Its Sights on $2 BillionManagement thinks it can get there with its latest drug approval.
Aug 6, 2018 by Brian Orelli, PhDHere's Why Antares Pharma Jumped TodayA deal with Pfizer has investors smiling, but there's no way to analyze the value to the company.
Aug 6, 2018 by Brian Orelli, PhDbluebird bio Prepares Its "Transition to a Commercial Company"The biotech expects to file a marketing application with EU regulators by the end of the year.
Aug 6, 2018 by Brian Orelli, PhDAlnylam Pharmaceuticals Is "Launch Ready"Now it just needs regulators to sign off on its marketing applications.
Aug 6, 2018 by Brian Orelli, PhDExelixis Gets the Patients EventuallyCompeting with immuno-oncology drugs might be hard, but being used after them is easy.
Aug 3, 2018 by Brian Orelli, PhDIDEXX Laboratories Is as Fit as a Butcher's DogIt was another solid quarter for the animal diagnostics company.
Aug 3, 2018 by Brian Orelli, PhDHere's Why Varex Imaging Stock Is Plummeting TodayTrade war woes have investors hitting the sell button.
Aug 2, 2018 by Brian Orelli, PhDQIAGEN Gets Efficient While It Waits for the Next Growth DriverEarnings grow faster than revenue as the diagnostic test company keeps costs in check.
Aug 2, 2018 by Brian Orelli, PhDHere's Why Exelixis Stock Jumped Higher TodayThe company hopped over investors' wall of worry.
Jul 31, 2018 by Brian Orelli, PhDHere's Why Castlight Health Plummeted TodayKeeping customers is important.
Jul 31, 2018 by Brian Orelli, PhDImmunoGen's Investors Play the Waiting GameCrucial data is expected in the first half of next year.
Jul 31, 2018 by Brian Orelli, PhDSeattle Genetics' Latest Approval Is the Best YetFrontline treatment of Hodgkin lymphoma drives Adcetris sales to new heights.
Jul 30, 2018 by Brian Orelli, PhDOn the Back of a Solid Quarter, Celgene Looks AheadRevlimid continues to grow, but management knows that can't last forever.
Jul 30, 2018 by Brian Orelli, PhDHere's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than RevenueThe biotech benefits from economies of scale.
